人端粒酶逆转录酶在肿瘤转录调控机制中的研究进展

doi:10.11904/j.issn.1002-3070.2023.01.012

摘要/Abstract

摘要： 人端粒酶逆转录酶(human telomerase reverse transcriptase,hTERT)是调节端粒酶活性的核心及限速成分,在调节端粒长度、保持基因稳定、调控肿瘤细胞的生长发育等方面发挥着极其重要的作用。近年来,hTERT在肿瘤转录调控机制方面的研究取得了新进展,对hTERT的研究已成为端粒酶研究的热点问题。TERT启动子突变的关键因子GA结合蛋白A、新型hTERT转录调控因子及hTERT高甲基化肿瘤区的发现均可能提供新的潜在治疗靶点。本文将从启动子突变、转录调控因子及表观遗传修饰对hTERT的转录调控进行综述,旨在为hTERT相关研究和开发以hTERT为靶点的药物提供理论基础。

关键词: 端粒酶, 人端粒酶逆转录酶, 启动子突变, 转录调控因子, 表观遗传修饰

Abstract: Human telomerase reverse transcriptase(hTERT) is the core and rate-limiting component of regulating telomerase activity.It plays an important role in regulating telomere length,maintaining gene stability,and regulating the growth and development of tumor cells.At present,the research on hTERT has become a hot issue in the research of telomerase.In recent years,the study of hTERT in the transcriptional regulation mechanism of tumor transcription has been made new progress.The discovery of GA-binding protein alpha,a key factor of TERT promoter mutation,novel hTERT transcriptional regulators,and hTERT hypermethylated tumor region may provide potential new therapeutic targets.This article will review the transcriptional regulation of hTERT from promoter mutations,transcriptional regulators and epigenetic modifications,aiming to lay a theoretical foundation for hTERT-related research and the development of hTERT-targeted drugs.

Key words: Telomerase, Human telomerase reverse transcriptase, Promoter mutations, Transcriptional regulators, Epigenetic modifications

中图分类号:

R551.3

曾平, 郭鹏翔, 骆横. 人端粒酶逆转录酶在肿瘤转录调控机制中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 68-72.

ZENG Ping, GUO Pengxiang, LUO Heng. Research progress of human telomerase reverse transcriptase in tumor transcriptional regulation mechanism[J]. Journal of Practical Oncology, 2023, 37(1): 68-72.

参考文献

1 Rossiello F,Jurk D,Passos JF,et al.Telomere dysfunction in ageing and age-related diseases[J].Nat Cell Biol,2022,24(2):135-147.
2 Kamal S,Junaid M,Ejaz A,et al.The secrets of telomerase:retrospective analysis and future prospects[J].Life Sci,2020,257:118115.
3 郭玥,吴霞,夏帆,等.端粒酶活性检测研究进展[J].分析测试学报,2021,40(12):1819-1826.
4 Yuan X,Dai M,Xu D.Telomere-related markers for cancer[J].Curr Top Med Chem,2020,20(6):410-432.
5 Stögbauer L,Stummer W,Senner V,et al.Telomerase activity,TERT expression,hTERT promoter alterations,and alternative lengthening of the telomeres(ALT)in meningiomas-a systematic review[J].Neurosurg Rev,2020,43(3):903-910.
6 Chakravarti D,LaBella KA,DePinho RA.Telomeres:history,health,and hallmarks of aging[J].Cell,2021,184(2):306-322.
7 Takakura M,Kyo S,Kanaya T,et al.Cloning of human telomerase catalytic subunit(hTERT)gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells[J].Cancer Res,1999,59(3):551-557.
8 Grill S,Nandakumar J.Molecular mechanisms of telomere biology disorders[J].Biol Chem,2021,296:100064.
9 Sizemore GM,Pitarresi JR,Balakrishnan S,et al.The ETS family of oncogenic transcription factors in solid tumours[J].Nat Rev Cancer,2017,17(6):337-351.
10 Yuan X,Dai M,Xu D.TERT promoter mutations and GABP transcription factors in carcinogenesis:more foes than friends[J].Cancer Lett,2020,493:1-9.
11 Lorbeer FK,Hockemeyer D.TERT promoter mutations and telomeres during tumorigenesis[J].Curr Opin Genet Dev,2020,60:56-62.
12 Papazacharias E,Kuhl S,Röhn G,et al.TERT and its binding protein:overexpression of GABPA/B in high grade gliomas[J].Oncotarget,2021,12(13):1271-1280.
13 Mancini A,Xavier-Magalhes A,Woods WS,et al.Disruption of the β1L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner[J].Cancer Cell,2018,34(3):513-528.
14 Liu R,Tan J,Shen X,et al.Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating surviving and TRAIL-R2[J].Proc Natl Acad Sci U S A,2021,118(11):e2022779118.
15 Fang Z,Zhang N,Yuan X,et al.GABPA-activated TGFBR2 transcription inhibits aggressiveness but is epigenetically erased by oncometabolites in renal cell carcinoma[J].J Exp Clin Cancer Res,2022,41(1):173.
16 Zhang S,Zhang K,Ji P,et al.GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma[J].BMC Cancer,2017,17(1):380.
17 Guo Y,Yuan X,Li K,et al.GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer[J].Cell Death Differ,2020,27(6):1862-1877.
18 Miao B,Zhang C,Stroh N,et al.Transcription factor TFE3 enhances cell cycle and cancer progression by binding to the hTERT promoter[J].Cancer Commun(Lond),2021,41(12):1423-1426.
19 Jie MM,Chang X,Zeng S,et al.Diverse regulatory manners of human telomerase reverse transcriptase[J].Cell Commun Signal,2019,17(1):63.
20 Kyo S,Takakura M,Fujiwara T,et al.Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers[J].Cancer Sci,2008,99(8):1528-1538.
21 Sinha-Datta U,Horikawa I,Michishita E,et al.Transcriptional activation of hTERT through the NF-κB pathway in HTLV-I–transformed cells[J].Blood,2004,104(8):2523-2531.
22 Ghosh A,Saginc G,Leow SC,et al.Telomerase directly regulates NF-κB-dependent transcription[J].Nat Cell Biol,2012,14(12):1270-1281.
23 Schafranek L,Nievergall E,Powell JA,et al.Sustained inhibition of STAT5,but not JAK2,is essential for TKI-induced cell death in chronic myeloid leukemia[J].Leukemia,2015,29(1):76-85.
24 Rondanin R,Simoni D,Romagnoli R,et al.Inhibition of activated STAT5 in Bcr/Abl expressing leukemia cells with new pimozide derivatives[J].Bioorg Med Chem Lett,2014,24(18):4568-4574.
25 Chai JH,Zhang Y,Tan WH,et al.Regulation of hTERT by BCR-ABL at multiple levels in K562 cells[J].BMC Cancer,2011,11(1):1-16.
26 Safa M,Jafari L,Alikarami F,et al.Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways[J].Tumour Biol,2017,39(6):1010428317705768.
27 Shahjahani M,Abroun A,Saki N,et al.STAT5:from pathogenesis mechanism to therapeutic approach in acute leukemia[J].Lab Med,2020,51(4):345-351.
28 Gong C,Yang H,Wang S,et al.hTERT promotes CRC proliferation and migration by recruiting YBX1 to increase NRF2 expression[J].Front Cell Dev Biol,2021,9:658101.
29 Liu T,Long Q,Li L,et al.The NRF2-dependent transcriptional axis,XRCC5/hTERT drives tumor progression and 5-Fu insensitivity in hepatocellular carcinoma[J].Mol Ther Oncolytics,2022,24:249-261.
30 Günes C,Lichtsteiner S,Vasserot AP,et al.Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1[J].Cancer Research,2000,60(8):2116-2121.
31 Gabet AS,Mortreux F,Charneau P,et al.Inactivation of hTERT transcription by Tax[J].Oncogene,2003,22(24):3734-3741.
32 Lai SR,Phipps SM,Liu L,et al.Epigenetic control of telomerase and modes of telomere maintenance in aging and abnormal systems[J].Front Biosci,2005,10(2):1779-1796.
33 Xiang H,Wang J,Mao Y,et al.Human telomerase accelerates growth of lens epithelial cells through regulation of the genes mediating RB/E2F pathway[J].Oncogene,2002,21(23):3784-3791.
34 Parulekar A,Choksi A,Taye N,et al.SMAR1 suppresses the cancer stem cell population via hTERT repression in colorectal cancer cells[J].Int J Biochem Cell Biol,2021,141:106085.
35 Choi SH,Cho KJ,Yun SH,et al.HKR3 regulates cell cycle through the inhibition of hTERT in hepatocellular carcinoma cell lines[J].J Cancer,2020,11(9):2442.
36 Lee DD,Leao R,Komosa M,et al.DNA hypermethylation within TERT promoter upregulates TERT expression in cancer[J].J Clin Invest,2019,129(1):223-229.
37 Lee DD,Komosa M,Nunes NM,et al.DNA methylation of the TERT promoter and its impact on human cancer[J].Curr Opin Genet Dev,2020,60:17-24.
38 Liu T,Yuan X,Xu D.Cancer-specific telomerase reverse transcriptase(TERT)promoter mutations:biological and clinical implications[J].Genes(Basel),2016,7(7):38.
39 Zhang X,Li B,de Jonge N,et al.The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression[J].Oncotarget,2015,6(7):4888-4900.
40 Asano N,Takeshima H,Yamashita S,et al.Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas[J].Sci Rep,2019,9(1):1-11.
41 Losi L,Lauriola A,Tazzioli E,et al.Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines[J].J Ovarian Res,2019,12(1):1-10.
42 Nguyen E,Richerolle A,Sánchez-Bellver J,et al.hTERT DNA methylation analysis identifies a biomarker for retinoic acid-induced hTERT repression in breast cancer cell lines[J].Biomedicines,2022,10(3):695.
43 Liu T,Yuan X,Xu D.Cancer-specific telomerase reverse transcriptase(TERT)promoter mutations:biological and clinical implications[J].Genes(Basel),2016,7(7):38.
44 Liu C,Fang X,Ge Z,et al.The telomerase reverse transcriptase(hTERT)gene is a direct target of the histone methyltransferase SMYD3[J].Cancer Res,2007,67(6):2626-2631.
45 Lewis KA,Tollefsbol TO.Regulation of the telomerase reverse transcriptase subunit through epigenetic mechanisms[J].Front Genet,2016,7:83.
46 Qing H,Aono J,Findeisen HM,et al.Differential regulation of telomerase reverse transcriptase promoter activation and protein degradation by histone deacetylase inhibition[J].J Cell Physiol,2016,231(6):1276-1282.
47 梁楠,程卯生,刘洋.新型组蛋白去乙酰化酶抑制剂-Abexinostat[J].临床药物治疗杂志,2022,20(2):18-21.

[1]	陈敏, 邢丽娜. 放射抗拒的宫颈癌细胞端粒酶活性对其放射敏感性影响的研究[J]. 实用肿瘤学杂志, 2013, 27(1): 17-20.
[2]	尤艳, 尤敏, 李国库, 耿敬姝, 孙国荣, 王红焰, 李海燕, 陈瑛. 脂溢性角化病皮损端粒酶活性的表达及其临床意义[J]. 实用肿瘤学杂志, 2011, 25(4): 306-309.
[3]	吕琳, 娄阁. 宫颈癌早期筛查方法研究进展[J]. 实用肿瘤学杂志, 2011, 25(4): 381-383.
[4]	闫红娇综述, 葛晓峰审校. 端粒酶抑制剂GRN163在乳腺癌综合治疗中的应用[J]. 实用肿瘤学杂志, 2009, 23(6): 586-589.
[5]	陈衍智, 赵翌综述, 李萍萍审校. 细胞衰老与肿瘤[J]. 实用肿瘤学杂志, 2009, 23(3): 261-264.
[6]	李刚;付成. 联合检测尿液中CYFRA21-1及端粒酶活性在膀胱癌早期诊断中的意义[J]. 实用肿瘤学杂志, 2008, 22(05): 417-419.
[7]	王波;殷新光;杨志宏;宋震亚;朱永良;赵奕. 胃癌、肠化及非典型增生患者外周血端粒酶抗体检测及其意义[J]. 实用肿瘤学杂志, 2007, 21(01): 42-43,8.
[8]	张海燕;谢丽微;高宝辉;谢小志;王宗敏;赵志光. 端粒酶逆转录酶及VEGF在卵巢肿瘤中的表达[J]. 实用肿瘤学杂志, 2005, 19(02): 128-131.
[9]	余志英;杜静;张金超;李丽文;初虹;柯玮琳. 紫杉醇对卵巢癌细胞端粒酶活性影响的研究[J]. 实用肿瘤学杂志, 2005, 19(02): 95-97.
[10]	张俊勇;葛秀兰;于英杰;刘吉勇;贾继东;王宝恩. 端粒酶活性检测鉴别良恶性腹水的临床价值[J]. 实用肿瘤学杂志, 2004, 18(02): 85-87.
[11]	王文龙;于秀艳;黄式敏;王振明. 脱落细胞端粒酶活性检测在良恶性胸腹水鉴别中的应用[J]. 实用肿瘤学杂志, 2004, 18(01): 54-55.
[12]	邢喆;赵岩;朱佳;赵莹. 胃镜活检标本端粒酶检测的临床意义[J]. 实用肿瘤学杂志, 2003, 17(04): 309-310.
[13]	潘立峰;王立华;周宝臣. 乳腺癌组织中端粒酶活性的研究[J]. 实用肿瘤学杂志, 2003, 17(01): 10-12.
[14]	赵金红;刘卫林;范业萍;阮承迈;陈守义;吴东林;张玉静;杨光荣;孙桂娟;蔡勇. 乳腺癌的hTERT基因表达和端粒酶活性关系分析[J]. 实用肿瘤学杂志, 2001, 15(04): 243-245.
[15]	翟晓波;鲍思蔚;关海桥;沙荣新;晏马成. 端粒酶活性法-新的肿瘤药敏方法的建立[J]. 实用肿瘤学杂志, 2001, 15(03): 184-185.